Track topics on Twitter Track topics that are important to you
Mirata BioPharma, LLC PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Mirata BioPharma, LLC articles that have been published worldwide.
We have published hundreds of Mirata BioPharma, LLC news stories on BioPortfolio along with dozens of Mirata BioPharma, LLC Clinical Trials and PubMed Articles about Mirata BioPharma, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mirata BioPharma, LLC Companies in our database. You can also find out about relevant Mirata BioPharma, LLC Drugs and Medications on this site too.
At the turn of the century, the pharmaceutical industry began a transition toward a focus on oncology, rare diseases, and other areas of high unmet need that required a new, more complex approach to drug development. For many of these disease states and novel approaches to therapy, traditional approaches to clinical trial design fall short and a number of innovative trial designs have emerged. In light of these changes, regulators across the globe are implementing new programs to provide regular development...
Neurodegenerative diseases commonly present misfolding and aggregation of one or more proteins, including α-synuclein, β-amyloid and tau. Several research efforts have been made to develop therapeutic agents able to reduce the neurotoxic effects of aggregated proteins. Among these, the inhibition of α-synuclein by small molecules has been considered a promising approach. Areas covered: New bis-heteroaryl derivatives based on the N-[1-(1H-indol-3-yl)hexan-2-yl]-1,3-thiazole-5-carboxamide scaffold with dif...
Epileptic spasms during infancy (infantile spasms) represent a serious treatment and social problem despite their rare occurrence. Current treatments include hormonal therapy (adrenocorticotropin-ACTH or corticosteroids) or vigabatrin (per se or in the combination). These treatments are partially effective and with potentially significant adverse effects. Thus, the search for new effective drugs is warranted. We tested efficacy of a novel fusion peptide AQB-565 developed by Aequus Biopharma in a model of in...